A clinical trial of DKN-01 in combination with atezolizumab (TECENTRIQ) +/- paclitaxel in advanced esophagogastric malignancies and in advanced biliary tract cancers.

Trial Profile

A clinical trial of DKN-01 in combination with atezolizumab (TECENTRIQ) +/- paclitaxel in advanced esophagogastric malignancies and in advanced biliary tract cancers.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs DKN 01 (Primary) ; Atezolizumab; Paclitaxel
  • Indications Biliary cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 New trial record
    • 08 Sep 2017 According to Leap Therapeutics media release, Leap Therapeutics will conduct this trial in collaboration with EORTC and Roche will supply atezolizumab to the EORTC for this study collaboration. Study is expected to begin enrolling patients in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top